LGND
Ligand Pharmaceuticals Incorporated
296.90$
-3.2%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.9% | +162.7% | -28.8% | +174.4% | -22.1% | -189.6% | – | -17.1% | +250.2% | +6.2% | -50.7% | – | |
| – | +9.5% | -7.1% | +1.0% | -17.7% | +18.4% | +8.3% | -4.4% | -23.2% | +40.3% | -14.6% | 0.0% | – | |
| – | -16.9% | +28.2% | +50.8% | +137.2% | -71.3% | +4.1% | +27.6% | +47.5% | -3.2% | -25.7% | +28.9% | – | |
| – | – | – | -192.3% | – | – | -144.5% | – | – | – | -36.6% | -219.0% | – | |
| – | -14.4% | -74.8% | +1,937.1% | +565.8% | -95.0% | -69.9% | +0.0% | -93.0% | -40.0% | +2,433.3% | -88.6% | – | |
| – | -47.3% | -63.3% | +1,350.6% | -15.1% | -17.0% | – | -318.0% | +3,213.4% | -94.9% | +421.1% | – | – | |
| – | +149.5% | +1,096.9% | – | – | – | – | – | – | -100.0% | – | – | – | |
| – | – | – | – | – | -40.0% | +16.7% | +0.0% | – | -98.0% | -100.1% | – | – | |
| – | +91.6% | +95.1% | -22.4% | +480.3% | -63.0% | -122.9% | – | +2,631.5% | -98.0% | -269.7% | – | – | |
| – | – | +637.7% | -217.7% | – | -80.9% | -379.9% | – | +264.4% | -50.4% | -268.3% | – | – | |
| – | -6.4% | +177.4% | -39.9% | +99.5% | +24.5% | -192.7% | – | -16.1% | +250.6% | +5.7% | -50.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.